Unicycive raises ATM capacity to $150M; files new $50M shelf registration

Unicycive Therapeutics, Inc.

Entered Amendment No. 2 to Sales Agreement with Guggenheim Securities on June 5, 2026.
ATM offering capacity increased from $100M to $150M in aggregate offering price.
Also filed a new S-3 registration statement to sell an additional $50M of common stock.
Previous agreements: initial Sales Agreement Nov 13, 2024; Amendment No. 1 Nov 14, 2025.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Unicycive Therapeutics, Inc. amended Amendment No. 2 to the Sales Agreement with Guggenheim Securities, LLC (effective 2026-06-05).

Action: amendment
Agreement: atm program
Counterparty: Guggenheim Securities, LLC
Effective: 2026-06-05

Exact text from the filing

On June 5, 2026, the Company entered into Amendment No. 2 to the Sales Agreement with the Agent (the “Amendment”) to increase the number of Shares that may be sold in the ATM Offering to $150,000,000.

View on SEC.gov

745 material agreements filed in the last 30 days. Browse all material agreements →

Unicycive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-26-065828

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.